The DNA methylome of glioblastoma multiforme

Neurobiology of Disease

Volumn 39, Issue 1, 2010, Pages 40-46

  Martinez, Ramon ^a   Esteller, Manel ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

DNA methylation; Glioblastoma multiforme; Hypermethylation; Hypomethylation; Microarrays

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ANGIOGENESIS; APOPTOSIS; CELL CYCLE; CELL MIGRATION; DNA ALKYLATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE DELETION; GENE LOCATION; GENE MUTATION; GENE SILENCING; GENOTYPE; GLIOBLASTOMA; HOMOZYGOSITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANIMALS; BRAIN NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLIOBLASTOMA; HUMANS;

EID: 77952888433     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.12.030     Document Type: Review

References (77)

1. Alaminos M., Dávalos V., Ropero S., Setién F., Paz M.F., Herranz M., Fraga M.F., Mora J., Cheung N.K., Gerald W.L., Esteller M. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 2005, 65:2565-2571.
2. Alonso M.E., Bello M.J., Gonzalez-Gomez P., Arjona D., Lomas J., de Campos J.M., Isla A., Sarasa J.L., Rey J.A. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet. Cytogenet. 2003, 144:134-142.
3. Aldape K.D., Okcu M.F., Bondy M.L., Wrensch M. Molecular epidemiology of glioblastoma. Cancer J. 2003, 9:99-106.
4. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., Baylin S.B., Graff J.R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999, 59:798-802.
5. Benjamin R., Capparella J., Brown A. Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J. 2003, 9:82-90.
6. Berdasco M., Ropero S., Setien F., Fraga M.F., Lapunzina P., Losson R., Alaminos M., Cheung N.K., Rahman N., Esteller M. Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl. Acad. Sci. U. S. A. 2009, (2009 Dec 14, Electronic publication ahead of print).
7. Boström J., Cobbers J.M., Wolter M., Tabatabai G., Weber R.G., Lichter P., Collins V.P., Reifenberger G. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998, 58:29-33.
8. Brandes A.A., Ermani M., Basso U., Amistà P., Berti F., Scienza R., Rotilio A., Pinna G., Gardiman M., Monfardini S. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann. Oncol. 2001, 12:255-257.
9. Brena R.M., Costello J.F. Genome-epigenome interactions in cancer. Hum. Mol. Genet. 2007, 16(Spec. No. 1):R96-R105.
10. Brena R.M., Plass C., Costello J.F. Mining methylation for early detection of common cancers. PLoS Med. 2006, 12:e479.
11. Cadieux B., Ching T.T., VandenBerg S.R., Costello J.F. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 2006, 66:8469-8476.
12. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
13. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
14. Ciafrè S.A., Galardi S., Mangiola A., Ferracin M., Liu C.G., Sabatino G., Negrini M., Maira G., Croce C.M., Farace M.G. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 2005, 334:1351-1358.
15. Collins V.P. Cellular mechanisms targeted during astrocytoma progression. Cancer Lett. 2002, 188:1-7.
16. Costello J.F., Frühwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomäki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24:132-138.
17. Costello J.F., Hong C., Plass C., Smiraglia D.J. Restriction landmark genomic scanning: analysis of CpG islands in genomes by 2D gel electrophoresis. Methods Mol. Biol. 2009, 507:131-148.
18. Dudley K.J., Revill K., Whitby P., Clayton R.N., Farrell W.E. Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol. Cancer Res. 2008, 6:1567-1574.
19. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002, 21:5427-5440.
20. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 2007, 16(Spec. No. 1):R50-R59.
21. Esteller M., Garcia-Foncillas J., Andion E., Goodman S., Vanaclocha V., Baylin S., Hermann J. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Eng. J. Med. 2000, 343:1350-1354.
22. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
23. Foltz G., Ryu G.Y., Yoon J.G., Nelson T., Fahey J., Frakes A., Lee H., Field L., Zander K., Sibenaller Z., Ryken T.C., Vibhakar R., Hood L., Madan A. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res. 2006, 66:6665-6674.
24. Foltz G., Yoon J.G., Lee H., Ryken T.C., Sibenaller Z., Ehrich M., Hood L., Madan A. DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis. Oncogene 2009, 28:2667-2677.
25. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28:5369-5380.
26. Godlewski J., Nowicki M.O., Bronisz A., Williams S., Otsuki A., Nuovo G., Raychaudhury A., Newton H.B., Chiocca E.A., Lawler S. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008, 68:9125-9130.
27. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
28. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
29. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
30. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9700-9704.
31. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995, 55:4525-4530.
32. Hong C., Moorefield K.S., Jun P., Aldape K.D., Kharbanda S., Phillips H.S., Costello J.F. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10974-10979.
33. Horiguchi K., Tomizawa Y., Tosaka M., Ishiuchi S., Kurihara H., Mori M., Saito N. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 2003, 22:7862-7865.
34. Ichimura K., Bolin M.B., Goike H.M., Schmidt E.E., Moshref A., Collins V.P. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000, 60:417-424.
35. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
36. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
37. Kantelhardt S.R., Leppert J., Krajewski J., Petkus N., Reusche E., Tronnier V.M., Hüttmann G., Giese A. Imaging of brain and brain tumor specimens by time-resolved multiphoton excitation microscopy ex vivo. Neuro-Oncol. 2007, 9:103-112.
38. Kim T.Y., Zhong S., Fields C.R., Kim J.H., Robertson K.D. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 2006, 66:7490-7501.
39. Kraus J.A., Wenghoefer M., Schmidt M.C., von Deimling A., Berweiler U., Roggendorf W., Heuser K., Reifenberger G., Schlegel U. Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J. Neurol. 2000, 247:455-460.
40. Kunitz A., Wolter M., van den Boom J., Felsberg J., Tews B., Hahn M., Benner A., Sabel M., Lichter P., Reifenberger G., von Deimling A., Hartmann C. DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in human gliomas. Brain Pathol. 2007, 17:363-370.
41. Lang F., Miller D., Koslow M., Newcomb E. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 1994, 81:427-436.
42. Louis D.N. A molecular genetic model of astrocytoma histopathology. Brain Pathol. 1997, 7:755-764.
43. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
44. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setién F., Casado S., Suarez-Gauthier A., Sanchez-Cespedes M., Git A., Spiteri I., Das P.P., Caldas C., Miska E., Esteller M. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67:1424-1429.
45. Martinez R., Schackert G., Yaya-Tur R., Rojas-Marcos I., Herman J.G., Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J. Neurooncol. 2007, 83:91-93.
46. Martinez R., Schackert G., Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J. Neurooncol. 2007, 82:133-139.
47. Martínez R., Setien F., Voelter C., Casado S., Quesada M.P., Schackert G., Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007, 28:1264-1268.
48. Martini M., Pallini R., Luongo G., Cenci T., Lucantoni C., Larocca L.M. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int. J. Cancer 2008, 123:2955-2960.
49. Mueller W., Nutt C.L., Ehrich M., Riemenschneider M.J., von Deimling A., van den Boom D., Louis D.N. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2007, 26:583-593.
50. Nakamura M., Watanabe T., Klangby U., Asker C., Wiman K., Yonekawa Y., Kleihues P., Ohgaki H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 2001, 11:159-168.
51. Nakamura M., Watanabe T., Yonekawa Y., Kleihues P., Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:CŽA:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 2001, 22:1715-1719.
52. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005, 64:479-489.
53. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007, 170:1445-1453.
54. Ohgaki H., Dessen P., Jourde B., Horstmann S., Nishikawa T., Di Patre P.L., Burkhard C., Schüler D., Probst-Hensch N.M., Maiorka P.C., Baeza N., Pisani P., Yonekawa Y., Yasargil M.G., Lütolf U.M., Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004, 64:6892-6899.
55. Papagiannakopoulos T., Shapiro A., Kosik K.S. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 2008, 68:8164-8172.
56. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
57. Pegg A.E., Dolan M.E., Moschel R.C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol. 1995, 51:167-223.
58. Riemenschneider M.J., Buschges R., Wolter M., Reifenberger J., Bostrom J., Kraus J.A., Schlegel U., Reifenberger G. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res. 1999, 59:6091-6096.
59. Silber J., Lim D.A., Petritsch C., Persson A.I., Maunakea A.K., Yu M., Vandenberg S.R., Ginzinger D.G., James C.D., Costello J.F., Bergers G., Weiss W.A., Alvarez-Buylla A., Hodgson J.G. MiR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med, 2008 Jun 24;6:14. Mol. Cell. Biol. 2008, 28:5369-5380.
60. Simpson D.J., Clayton R.N., Farrell W.E. Preferential loss of death associated protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 2002, 21:1217-1224.
61. Stone A.R., Bobo W., Brat D.J., Devi N.S., Van Meir E.G., Vertino P.M. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am. J. Pathol. 2004, 165:1151-1161.
62. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7:359-360.
63. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
64. Tang X., Khuri F.R., Lee J.J., Kemp B.L., Liu D., Hong W.K., Mao L. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl. Cancer Inst. 2000, 92:1511-1516.
65. Tepel M., Roerig P., Wolter M., Gutmann D.H., Perry A., Reifenberger G., Riemenschneider M.J. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int. J. Cancer 2008, 123:2080-2086.
66. Terasawa K., Sagae S., Toyota M., Tsukada K., Ogi K., Satoh A., Mita H., Imai K., Tokino T., Kudo R. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin. Cancer Res. 2004, 10:2000-2006.
67. Tews B., Roerig P., Hartmann C., Hahn M., Felsberg J., Blaschke B., Sabel M., Kunitz A., Toedt G., Neben K., Benner A., Deimling A.V., Reifenberger G., Lichter P. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene 2007, 26:5010-5016.
68. Uhlmann K., Rohde K., Zeller C., Szymas J., Vogel S., Marczinek K., Thiel G., Nurnberg P., Laird P.W. Distinct methylation profiles of glioma subtypes. Int. J. Cancer 2003, 106:52-59.
69. van den Boom J., Wolter M., Blaschke B., Knobbe C.B., Reifenberger G. Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int. J. Cancer 2006, 119:2330-2338.
70. Veeriah S., Brennan C., Meng S., Singh B., Fagin J.A., Solit D.B., Paty P.B., Rohle D., Vivanco I., Chmielecki J., Pao W., Ladanyi M., Gerald W.L., Liau L., Cloughesy T.C., Mischel P.S., Sander C., Taylor B., Schultz N., Major J., Heguy A., Fang F., Mellinghoff I.K., Chan T.A. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:9435-9440.
71. von Deimling A., Louis D.N., von Ammon K., Petersen I., Yasargil M.G., Wiestler O.D., Seizinger B.R. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg. 1992, 77:295-301.
72. von Deimling A., Louis D.N., Wiestler O.D. Molecular pathways in the formation of gliomas. Glia 1995, 15:328-338.
73. Waha A., Güntner S., Huang T.H., Yan P.S., Arslan B., Pietsch T., Wiestler O.D., Waha A. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 2005, 7:193-199.
74. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157-158.
75. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009, 360:765-773.
76. Yi J.M., Tsai H.C., Glöckner S.C., Lin S., Ohm J.E., Easwaran H., James C.D., Costello J.F., Riggins G., Eberhart C.G., Laterra J., Vescovi A.L., Ahuja N., Herman J.G., Schuebel K.E., Baylin S.B. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008, 68:8094-8103.
77. Zhao X.D., Han X., Chew J.L., Liu J., Chiu K.P., Choo A., Orlov Y.L., Sung W.K., Shahab A., Kuznetsov V.A., Bourque G., Oh S., Ruan Y., Ng H.H., Wei C.L. Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 2007, 1:286-298.